DGNews
Cataract surgery among patients with age-related macular degeneration (AMD) who are being treated with either bevacizumab or ranibizumab does not lead to an increase in the rate of progression from the dry to the wet form of the disease, according to a large retrospective trial presented here on May 3 at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting.